Detalhe da pesquisa
1.
The comparison of safety and cost between reference drug of rituximab and its biosimilar Riximyo in lymphoproliferative disorders and other hematological diseases. Single center experience.
Leuk Lymphoma
; 65(1): 55-61, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37888870
2.
National and subnational short-term forecasting of COVID-19 in Germany and Poland during early 2021.
Commun Med (Lond)
; 2(1): 136, 2022 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-36352249